Table 3
Open in new tab

Absolute percentage annual risk of ICH stratified by stroke risk in patients with non-valvular AF receiving oral anticoagulation therapy for stroke prevention. Adapted from Rognoni et al.62

Intracranial bleeding, absolute annual risk (%)
CHADS2 ≤ 1CHADS2 = 2CHADS2 ≥ 3
Warfarin0.480.651.01
Rivaroxaban (20 mg od)Not investigated0.440.68
Apixaban (5 mg bid)0.20.270.42
Dabigatran (150 mg bid)0.20.260.52
Intracranial bleeding, absolute annual risk (%)
CHADS2 ≤ 1CHADS2 = 2CHADS2 ≥ 3
Warfarin0.480.651.01
Rivaroxaban (20 mg od)Not investigated0.440.68
Apixaban (5 mg bid)0.20.270.42
Dabigatran (150 mg bid)0.20.260.52

bid, twice daily; CHADS2, Congestive heart failure, Hypertension, Age ≥75 years, Diabetes mellitus, prior Stroke/transient ischaemic attack (doubled); od, once daily; ICH, intracranial haemorrhage.

Table 3
Open in new tab

Absolute percentage annual risk of ICH stratified by stroke risk in patients with non-valvular AF receiving oral anticoagulation therapy for stroke prevention. Adapted from Rognoni et al.62

Intracranial bleeding, absolute annual risk (%)
CHADS2 ≤ 1CHADS2 = 2CHADS2 ≥ 3
Warfarin0.480.651.01
Rivaroxaban (20 mg od)Not investigated0.440.68
Apixaban (5 mg bid)0.20.270.42
Dabigatran (150 mg bid)0.20.260.52
Intracranial bleeding, absolute annual risk (%)
CHADS2 ≤ 1CHADS2 = 2CHADS2 ≥ 3
Warfarin0.480.651.01
Rivaroxaban (20 mg od)Not investigated0.440.68
Apixaban (5 mg bid)0.20.270.42
Dabigatran (150 mg bid)0.20.260.52

bid, twice daily; CHADS2, Congestive heart failure, Hypertension, Age ≥75 years, Diabetes mellitus, prior Stroke/transient ischaemic attack (doubled); od, once daily; ICH, intracranial haemorrhage.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close